Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
Keith Wheatley(Cancer Research UK Clinical Trials Unit), Stefan Suciu(St James's University Hospital), Alexander M.M. Eggermont(University Medical Center Utrecht), Natalie Ives(Cancer Research UK Clinical Trials Unit), Barry W. Hancock(Weston Park Cancer Centre), Martin Gore(Imperial College London)
Cited by 344
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k